A new NCL-targeting aptamer-drug conjugate as a promising therapy against esophageal cancer.

J Nanobiotechnology · 2025 · PMC11773979 · PMID 39875991

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

5 J, compared with the control group, the number of esophageal cancer cell clones formed by AS1411-HSA-LDP-AE at a low concentration (12.5 ng/mL) showed a decreasing trend.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.